Breakthrough COVID-19 infection in people with MS after SARS-CoV-2 vaccination: Should we still be concerned?
作者信息
Van Kempen Zoé LE, Mazziotti Valentina
机构信息
Department of Neurology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.
Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy/IRCCS Istituto Centro S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy.
出版信息
Mult Scler. 2023 Jul;29(8):901-903. doi: 10.1177/13524585231185249.
Abstract
摘要
相似文献
1
Breakthrough COVID-19 infection in people with MS after SARS-CoV-2 vaccination: Should we still be concerned?
Mult Scler. 2023 Jul;29(8):901-903. doi: 10.1177/13524585231185249.
2
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun.
3
Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
Vaccine. 2023 Aug 31;41(38):5655-5661. doi: 10.1016/j.vaccine.2023.07.043. Epub 2023 Aug 4.
4
A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.
Eur J Med Res. 2023 Nov 26;28(1):542. doi: 10.1186/s40001-023-01531-7.
5
Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
J Hosp Infect. 2023 Feb;132:46-51. doi: 10.1016/j.jhin.2022.11.016. Epub 2022 Dec 5.
6
Vaccines for preventing infections in adults with haematological malignancies.
Cochrane Database Syst Rev. 2025 May 21;5(5):CD015530. doi: 10.1002/14651858.CD015530.pub2.
7
Role of senescent CD4 T cells in breakthrough infection of the new variant strain of SARS-CoV-2 in elderly patients.
J Transl Med. 2025 Jul 3;23(1):737. doi: 10.1186/s12967-025-06756-0.
8
Characteristics of humoral responses to the first coronavirus disease booster vaccine and breakthrough infection in central China: a multicentre, prospective, longitudinal cohort study.
Front Immunol. 2025 Jan 7;15:1446751. doi: 10.3389/fimmu.2024.1446751. eCollection 2024.
9
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
10
Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis.
Int J Environ Res Public Health. 2022 Sep 29;19(19):12422. doi: 10.3390/ijerph191912422.
本文引用的文献
1
Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
Mult Scler. 2023 Jul;29(8):990-1000. doi: 10.1177/13524585231185246.
2
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
Mult Scler. 2023 Jul;29(8):979-989. doi: 10.1177/13524585231185247.
3
SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):280-283. doi: 10.1136/jnnp-2022-330100. Epub 2022 Dec 23.
4
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.
Ann Clin Transl Neurol. 2022 Aug;9(8):1321-1331. doi: 10.1002/acn3.51628. Epub 2022 Jul 19.
5
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Mult Scler. 2022 Nov;28(13):2106-2111. doi: 10.1177/13524585221102918. Epub 2022 Jun 23.
6
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
7
COVID-19 Vaccine Response in People with Multiple Sclerosis.
Ann Neurol. 2022 Jan;91(1):89-100. doi: 10.1002/ana.26251. Epub 2021 Nov 17.
8
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
J Neuroimmunol. 2021 Dec 15;361:577746. doi: 10.1016/j.jneuroim.2021.577746. Epub 2021 Oct 9.
9
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Neurology. 2021 Nov 9;97(19):e1870-e1885. doi: 10.1212/WNL.0000000000012753. Epub 2021 Oct 5.
10
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Mult Scler. 2021 May;27(6):864-870. doi: 10.1177/13524585211003476. Epub 2021 Apr 15.
Zotero 插件